Pulmatrix Current Ratio 2014-2022 | PULM
Pulmatrix current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Pulmatrix Current Ratio Historical Data |
Date |
Current Assets |
Current Liabilities |
Current Ratio |
2022-09-30 |
$0.04B |
$0.01B |
6.84 |
2022-06-30 |
$0.05B |
$0.01B |
8.19 |
2022-03-31 |
$0.05B |
$0.01B |
9.41 |
2021-12-31 |
$0.06B |
$0.00B |
12.33 |
2021-09-30 |
$0.05B |
$0.01B |
10.61 |
2021-06-30 |
$0.06B |
$0.01B |
8.74 |
2021-03-31 |
$0.06B |
$0.01B |
9.10 |
2020-12-31 |
$0.03B |
$0.01B |
3.97 |
2020-09-30 |
$0.04B |
$0.01B |
3.51 |
2020-06-30 |
$0.03B |
$0.02B |
1.99 |
2020-03-31 |
$0.03B |
$0.02B |
1.51 |
2019-12-31 |
$0.03B |
$0.02B |
1.83 |
2019-09-30 |
$0.03B |
$0.01B |
2.46 |
2019-06-30 |
$0.03B |
$0.01B |
2.58 |
2019-03-31 |
$0.00B |
$0.00B |
0.89 |
2018-12-31 |
$0.00B |
$0.00B |
1.14 |
2018-09-30 |
$0.01B |
$0.00B |
1.29 |
2018-06-30 |
$0.01B |
$0.00B |
2.37 |
2018-03-31 |
$0.00B |
$0.01B |
0.33 |
2017-12-31 |
$0.00B |
$0.01B |
0.73 |
2017-09-30 |
$0.01B |
$0.01B |
1.16 |
2017-06-30 |
$0.01B |
$0.01B |
1.99 |
2017-03-31 |
$0.01B |
$0.00B |
2.53 |
2016-12-31 |
$0.01B |
$0.01B |
1.02 |
2016-09-30 |
$0.01B |
$0.00B |
2.03 |
2016-06-30 |
$0.01B |
$0.00B |
2.87 |
2016-03-31 |
$0.02B |
$0.00B |
3.93 |
2015-12-31 |
$0.02B |
$0.00B |
5.68 |
2015-09-30 |
$0.02B |
$0.00B |
9.44 |
2015-06-30 |
$0.03B |
$0.00B |
19.61 |
2015-03-31 |
$0.00B |
|
0.00 |
2014-12-31 |
$0.00B |
$0.04B |
0.02 |
2014-09-30 |
$0.01B |
$0.00B |
22.90 |
2014-06-30 |
$0.02B |
$0.00B |
26.63 |
2014-03-31 |
$0.02B |
$0.00B |
16.45 |
2013-12-31 |
$0.00B |
|
0.00 |
2013-09-30 |
$0.00B |
|
0.00 |
2013-06-30 |
$0.00B |
|
0.00 |
2013-03-31 |
$0.00B |
$0.00B |
1.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.014B |
$0.005B |
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|